GEN Exclusives

More »

GEN News Highlights

More »
Jul 7, 2008

Althea and Protein’eXpert to Couple Respective Manufacturing and Research Services

  • Althea Technologies and Protein'eXpert plan on offering their services under a complementary commercialization partnership. While Althea Technologies provides manufacturing services,  Protein'eXpert is a contract research organization.

    Clients will gain access to Protein'eXpert's protein engineering, process development, and optimization expertise, with the full realm of cGMP manufacturing resources for production and fill/finish services from Phase I to commercial manufacturing provided by Althea.

    The firms hope that the combination of these complementary service will allow both companies to reach larger markets, broaden services for new and challenging products, and to better match early- and late-stage client requirements for protein projects.

    “The partnership with Althea Technologies is a great opportunity for us,” remarks Tristan Rousselle, Ph.D., CEO of Protein'eXpert. “Their very strong position on the U.S. market and their outstanding production facilities shall perfectly complement our expertise and set of services based on recombinant protein engineering as well as development- and small-scale cGMP production.”

    “We are confident,” states Magda Marquet, president and co-CEO of Althea, “that this will strengthen Althea's presence in Europe and provide Althea clients valuable early-stage process development capabilities.”



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?